The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis

The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study

Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment.

Study Overview

• Status: Active, not recruiting
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: Acthar Injectable Product; Drug: Depo medrol

Detailed Description

Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment. At screening visit, inclusion and exclusion criteria will be assessed. If assessments have not been completed to verify these criteria, they will be performed at this visit. After patients are confirmed to meet criteria, patient disease activity will be assessed and blood draw, synovial aspiration, and biopsy will be performed before first treatment injection. About 5 days after this first treatment injection, these assessment and samples will be performed again. About 5-6 weeks after first treatment injection, a final physician assessment will be performed. Patients will have the option of consenting to allow storage of samples for future research.

• Study Type: Interventional
• Enrollment (Estimated): 6
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Beverly Hills, California, United States, 90211
      • Attune Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Anti-Cyclic Citrullinated Peptide positive rheumatoid arthritis
• on a stable regimen of medications
• moderate to severe disease activity as measured by the Clinical Disease activity index (CDAI), or DAS28 (Disease Activity Score) within 30 days of starting the study

• Patients must have at least one joint with the following features within 30 days of starting the study:

  1. Joint must be tender
  2. Joint must be swollen
  3. Joint must have +2 or +3 doppler signal by ultrasound exam
  4. Joint must have +2 or +3 gray scale synovitis by ultrasound exam e. Joint must be amenable to synovial biopsy.

  f. Clinician assessing the joint must conclude, with a reasonable degree of certainty, that the swelling and tenderness observed in the joint is caused by rheumatoid arthritis, and not by another arthritic condition such as osteoarthritis, crystal arthritis, or infection.

Exclusion Criteria:

• Patients on anti-coagulation therapy
• Patients with an active infection
• Patients receiving oral corticosteroids within 5 days of enrollment, or parenteral corticosteroids within 3 weeks of enrollment (unless deemed able to taper off medication under investigator oversight and supervision)
• Patients with any history of joint infection
• Patients with a history of tuberculosis or coccidioidomycosis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Acthar; 80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.	Drug: Acthar Injectable Product; Acthar is a non-specific melanocortin receptor agonist; Other Names: repository corticotropin injection; H.P. Acthar Gel
Active Comparator: Depo Medrol; 40 milligrams of Depo Medrol will be injected intramuscularly one time	Drug: Depo medrol; Depo medrol is an anti-inflammatory glucocorticoid; Other Names: methylprednisolone acetate injectable suspension

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Degree of inflammation after short term treatment, as measured by a pathologist during histological assessment	Samples will be sectioned and stained with Haemotoxylin and Eosin and a pathologist blind to treatment will examine the sections under a microscope to determine whether or not inflammation is present compared to how healthy samples would be expected to appear.	Samples collected about 30 minutes before first treatment injection and about five days after this first injection
Initial degree of inflammation, as measured by a pathologist during histological assessment	Samples will be sectioned and stained with Haemotoxylin and Eosin and a pathologist blind to treatment will examine the sections under a microscope to determine whether or not inflammation is present compared to how healthy samples would be expected to appear.	Samples collected about five days after first injection of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Initial disease activity as measured by blinded clinician using DAS28 (Disease Activity Score)	In DAS28, a clinician assesses 28 specified joints for tenderness and swelling. A blood draw is performed at time of assessment to measure Erythrocyte Sedimentation Rate (in mm/h). The patient global health assessment (from 0=best to 100=worst) is also used. A specific algorithm is used to calculate the DAS28 score, using the measurements obtained as variables that plug into the algorithm.	Assessments are performed about 1 hour before first treatment injection
Disease activity after short-term treatment as measured by blinded clinician using DAS28 (Disease Activity Score)	In DAS28, a clinician assesses 28 specified joints for tenderness and swelling. A blood draw is performed at time of assessment to measure Erythrocyte Sedimentation Rate (in mm/h). The patient global health assessment (from 0=best to 100=worst) is also used. A specific algorithm is used to calculate the DAS28 score, using the measurements obtained as variables that plug into the algorithm.	Assessments are performed about 5 days after first treatment injection
Disease activity after long-term treatment as measured by blinded clinician using DAS28 (Disease Activity Score)	In DAS28, a clinician assesses 28 specified joints for tenderness and swelling. A blood draw is performed at time of assessment to measure Erythrocyte Sedimentation Rate (in mm/h). The patient global health assessment (from 0=best to 100=worst) is also used. A specific algorithm is used to calculate the DAS28 score, using the measurements obtained as variables that plug into the algorithm.	Assessments are performed about 5-6 weeks after first treatment injection.
Initial number of tender and swollen joints as measured by clinician while palpating 28 specified joints	A clinician assesses 28 specified joints for tenderness and swelling.	Assessments are performed about 1 hour before first treatment injection
Number of tender and swollen joints after short-term treatment as measured by clinician while palpating 28 specified joints	A clinician assesses 28 specified joints for tenderness and swelling.	Assessments are performed about 5 days after first treatment injection
Number of tender and swollen joints after long-term treatment as measured by clinician while palpating 28 specified joints	A clinician assesses 28 specified joints for tenderness and swelling.	Assessments are performed about 5-6 weeks after first treatment injection.
Initial Erythrocyte Sedimentation Rate (ESR) present in blood (in mm/h)	The Westergren method requires collecting 2 ml of venous blood into a tube containing 0 .5 ml of sodium citrate. It should be stored no longer than 2 hours at room temperature or 6 hours at 4 °C. The blood is drawn into a Westergren-Katz tube to the 200 mm mark. The tube is placed in a rack in a strictly vertical position for 1 hour at room temperature, at which time the distance from the lowest point of the surface meniscus to the upper limit of the red cell sediment is measured. The distance of fall of erythrocytes, expressed as millimeters in 1 hour, is the Erythrocyte Sedimentation Rate.	Assessments are performed about 1 hour before first treatment injection
Erythrocyte Sedimentation Rate (ESR) present in blood (in mm/h) after short-term treatment	The Westergren method requires collecting 2 ml of venous blood into a tube containing 0 .5 ml of sodium citrate. It should be stored no longer than 2 hours at room temperature or 6 hours at 4 °C. The blood is drawn into a Westergren-Katz tube to the 200 mm mark. The tube is placed in a rack in a strictly vertical position for 1 hour at room temperature, at which time the distance from the lowest point of the surface meniscus to the upper limit of the red cell sediment is measured. The distance of fall of erythrocytes, expressed as millimeters in 1 hour, is the Erythrocyte Sedimentation Rate.	Assessments are performed about 5 days after first treatment injection
Erythrocyte Sedimentation Rate (ESR) present in blood (in mm/h) after long-term treatment	The Westergren method requires collecting 2 ml of venous blood into a tube containing 0 .5 ml of sodium citrate. It should be stored no longer than 2 hours at room temperature or 6 hours at 4 °C. The blood is drawn into a Westergren-Katz tube to the 200 mm mark. The tube is placed in a rack in a strictly vertical position for 1 hour at room temperature, at which time the distance from the lowest point of the surface meniscus to the upper limit of the red cell sediment is measured. The distance of fall of erythrocytes, expressed as millimeters in 1 hour, is the Erythrocyte Sedimentation Rate.	Assessments are performed about 5-6 weeks after first treatment injection.
Initial patient global health assessment measured by the patient (from 0=best to 100=worst)	A patient is asked to rate their general global health on a scale from 0 to 100	Assessments are performed about 1 hour before first treatment injection
Patient global health assessment measured by the patient (from 0=best to 100=worst) after short-term treatment	A patient is asked to rate their general global health on a scale from 0 to 100	Assessments are performed about 5 days after first treatment injection
Patient global health assessment measured by the patient (from 0=best to 100=worst) after long-term treatment	A patient is asked to rate their general global health on a scale from 0 to 100	Assessments are performed about 5-6 weeks after first treatment injection.

Collaborators and Investigators

• Sponsor: Attune Health Research, Inc.
• Collaborators: Mallinckrodt
• Investigators: Principal Investigator: Swamy R Venuturupalli, MD, FACR, CEO

Study record dates

Study Major Dates

• Study Start (Actual): October 2, 2018
• Primary Completion (Actual): February 26, 2020
• Study Completion (Estimated): December 3, 2024

Study Registration Dates

• First Submitted: April 10, 2018
• First Submitted That Met QC Criteria: April 26, 2018
• First Posted (Actual): April 30, 2018

Study Record Updates

• Last Update Posted (Actual): January 30, 2024
• Last Update Submitted That Met QC Criteria: January 29, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Inflammation; Physiological Effects of Drugs; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Neuroprotective Agents; Protective Agents; Prednisolone; Methylprednisolone Acetate; Methylprednisolone; Methylprednisolone Hemisuccinate; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Adrenocorticotropic Hormone
• Other Study ID Numbers: 32971

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes